Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375493 | 0.83 | CNR2 (0.42) | POLB | |
| SCHEMBL4030977 | 0.80 | EGFR (0.40) | NPC1RAB9AEGFRSRCKDM4E | |
| SCHEMBL27168761 | 0.75 | MTNR1A (0.45) | GFER | |
| SCHEMBL27168709 | 0.75 | IL1R1 (0.46) | EGFRKDM4ELMNAHTTL3MBTL1 | |
| SCHEMBL14861105 | 0.74 | CA12 (0.61) | POLB | |
| SCHEMBL6961215 | 0.74 | CA12 (0.61) | POLB | |
| SCHEMBL13073331 | 0.74 | CA12 (0.61) | POLB | |
| SCHEMBL1257540 | 0.74 | CTRB1 (0.40) | — | |
| SCHEMBL1257536 | 0.74 | CTRB1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL7759019 | 0.73 | CA12 (0.60) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513811-B1 | NON-PEPTIDIC BRS-3 AGONISTS | SOLVAY PHARM GMBH (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7244743-B2 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1513811-A1 | NON-PEPTIDIC BRS-3 AGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104196-A1 | NON-PEPTIDIC BRS-3 AGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | BRS3, NPR3, ADRB3 | NPC1 1086/4885RAB9A 1591/4885EGFR 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.